Clinical trial · Observational
Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection
Evaluation of Oral Epigallocatechin Gallate Treatment for Low-grade Cervical Lesions (L-SIL) Associated With Human Papilloma Virus (HPV) Infection
NCT06314113CI-TRIAL-00075063EGCG-HPVunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Low-Grade Intraepithelial Neoplasia of Cervix | Low Grade Cervical Intraepithelial Neoplasia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epigallocatechin Gallate | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Low-grade Cervical Lesions (L-SIL)
- description
- Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection
- interventionNames
- Dietary Supplement: Epigallocatechin Gallate
Primary outcomes (1)
- measure
- Persistence
- timeFrame
- After 6, 12, 18, and 24 months from the recruitment
- description
- Persistence of Low-grade Cervical Lesions (L-SIL), evaluated by pap smear
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Women affected by Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) Infection Exclusion Criteria: * Pregnancy * Concomitant pathologies causing immunosuppression * Concurrent Immunomodulatory therapies * Hormone replacement therapy * High-grade Cervical Lesions (H-SIL) or in situ adenocarcinoma * Previous history of L-SIL or higher grade lesions ≥ 24 months
References
Publications (0)
Data not yet available
No reference posted for this study.